Compare UHT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | EOLS |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.5M | 550.9M |
| IPO Year | 1995 | 2018 |
| Metric | UHT | EOLS |
|---|---|---|
| Price | $41.84 | $8.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $43.00 | $15.50 |
| AVG Volume (30 Days) | 88.8K | ★ 953.4K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.79 | N/A |
| Revenue | $99,190,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $2.12 | $13.27 |
| Revenue Next Year | $2.94 | $17.62 |
| P/E Ratio | $52.20 | ★ N/A |
| Revenue Growth | 0.18 | ★ 11.61 |
| 52 Week Low | $35.26 | $3.86 |
| 52 Week High | $46.30 | $8.69 |
| Indicator | UHT | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 70.01 |
| Support Level | $39.72 | $5.78 |
| Resistance Level | $43.06 | N/A |
| Average True Range (ATR) | 1.04 | 0.46 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 52.12 | 96.91 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.